#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13146	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2538	638.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1946	1946	T	812	T,C,G	809,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13146	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2538	638.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1680	1680	C	867	C,T	866,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13146	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2538	638.7	0	HET	.	.	.	A69G	.	69	69	A	565	565	A	857	A,G	674,182	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22580	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4093	687.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1958	1958	A	881	A,T	880,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22580	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4093	687.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2592	2592	C	792	C	792	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22580	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4093	687.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2666	2666	A	793	A,T,G	791,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22580	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4093	687.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3218	3218	C	800	C,G,T	798,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	1968	folP	852	852	99.88	folP.l15.c4.ctg.1	2016	121.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1000	1002	AAA	191;192;192	A;A;A,G	190;191;190,1	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	1968	folP	852	852	99.88	folP.l15.c4.ctg.1	2016	121.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1231	1233	AGC	221;218;218	A;G;C,A	221;217;214,2	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4842	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3837	156.9	1	SNP	p	S91F	0	.	.	271	273	TCC	870	872	TCC	169;169;169	T,A;C,A;C	167,1;167,1;168	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4842	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3837	156.9	1	SNP	p	D95G	0	.	.	283	285	GAC	882	884	GAC	174;173;172	G;A;C	174;173;172	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4842	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3837	156.9	1	SNP	p	D95N	0	.	.	283	285	GAC	882	884	GAC	174;173;172	G;A;C	174;173;172	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1836	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1746	131.1	1	SNP	p	G45D	0	.	.	133	135	GGC	664	666	GGC	213;214;215	G,A;G;C	212,1;214;215	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	980	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1377	88.3	0	.	n	.	0	A197.	DEL	197	197	A	772	772	A	188	A	187	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4482	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3516	158.9	1	SNP	p	D86N	0	.	.	256	258	GAC	842	844	GAC	192;191;192	G;A,C;C	192;190,1;192	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4482	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3516	158.9	1	SNP	p	S87W	0	.	.	259	261	AGT	845	847	AGT	193;195;195	A;G;T	193;195;195	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4482	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3516	158.9	1	SNP	p	S87I	0	.	.	259	261	AGT	845	847	AGT	193;195;195	A;G;T	193;195;195	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4482	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3516	158.9	1	SNP	p	S87R	0	.	.	259	261	AGT	845	847	AGT	193;195;195	A;G;T	193;195;195	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4482	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3516	158.9	1	SNP	p	S88P	0	.	.	262	264	TCC	848	850	TCC	194;195;197	T;C,A;C	194;194,1;197	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3922	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3128	156.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1744	1746	GGC	220;219;218	G;G,A;C,A	220;218,1;217,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1457	1459	GCA	179;179;178	G;C;A	179;179;178	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1460	1462	ATC	181;182;181	A;T,A;CAAA,CAA	181;181,1;173,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1472	1474	GTG	185;186;189	G,T;T;G	184,1;186;189	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1472	1474	GTG	185;186;189	G,T;T;G	184,1;186;189	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1976	1978	ACC	191;193;194	A;C;C	191;192;193	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2030	2032	GCG	188;188;186	G;C,T;G	188;187,1;186	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2030	2032	GCG	188;188;186	G;C,T;G	188;187,1;186	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2153	2155	GGC	210;210;209	G,C;G;C	209,1;210;209	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2162	2164	GGC	203;200;199	G;G;C	203;200;199	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3504	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2802	155.5	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2180	2182	CTG	206;206;207	C;T;G,T	206;206;206,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5118	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3505	181.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1803	1805	CCG	210;210;212	C,A,T;C;G,A	208,1,1;210;211,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2256	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2415	116.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	880	880	C	168	C	167	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	104	94.23	porB1a.l15.c4.ctg.3	185	37.2	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	46;44;41	A;C;G	46;44;41	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	104	94.23	porB1a.l15.c4.ctg.3	185	37.2	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	21;19;16	C;A;A	21;19;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	104	94.23	porB1a.l15.c4.ctg.3	185	37.2	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	181	183	TAC	6;6;1	T;A;C	6;6;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	26;31;34	T;T;A	26;31;34	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	73;73;73	C;A;T	73;73;73	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	73;73;73	A;G;T	73;73;73	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	74;74;74	T;A;C	74;74;74	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;2	T;C;G	3;3;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	276	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	368	35.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	568	570	GAA	198;198;198	G,A;A;A	197,1;198;198	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	856	858	GAT	207;207;207	G,T;A;T	206,1;206;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	979	981	TCA	230;229;228	T,G,C;C;A	228,1,1;229;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1108	1110	GTC	211;213;215	G,T,A;T;C	209,1,1;213;215	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1120	1122	TCT	216;217;220	T;C;T	216;217;220	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1438	1440	GCA	191;191;191	G,A;C,A,G;A	190,1;189,1,1;191	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	1	SNP	p	G120K	1	.	.	358	360	AAG	814	816	AAG	207;206;207	A;A,T;G	207;204,2;207	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	1	SNP	p	A121D	1	.	.	361	363	GAC	817	819	GAC	209;210;210	G,C,A;A,C;C	207,1,1;209,1;210	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2442	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1957	154.8	1	SNP	p	D121N	0	.	.	361	363	GAC	817	819	GAC	209;210;210	G,C,A;A,C;C	207,1,1;209,1;210	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	8356	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5420	192.3	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2271	2273	AAT	221;220;222	A;A,T;T,C	221;219,1;221,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1298	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1649	98.0	1	SNP	p	V57M	1	.	.	169	171	ATG	751	753	ATG	232;235;234	A;T,G;G	232;234,1;234	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
